In lung cancer, anti-PD-1/PD-L1 therapies have already been approved, as in advanced-stage NSCLC patients, monoclonal antibodies that target PD-1 and its main ligand PD-L1 have shown survival increments [129,149]. Here, PDCD1 is linked to non-small cell lung carcinoma.